Whitehawk Therapeutics, Inc. (WHWK) - Total Assets
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) holds total assets worth $167.02 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Whitehawk Therapeutics, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see WHWK market cap overview for the company's overall valuation and market capitalisation.
Whitehawk Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Whitehawk Therapeutics, Inc.'s total assets of $167.02 Million consist of 87.2% current assets and 12.8% non-current assets. Review WHWK liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.8% |
| Accounts Receivable | $5.90 Million | 8.4% |
| Inventory | $5.31 Million | 7.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Whitehawk Therapeutics, Inc. (WHWK) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Whitehawk Therapeutics, Inc.'s current assets represent 87.2% of total assets in 2024, a decrease from 97.9% in 2019.
- Cash Position: Cash and equivalents constituted 40.8% of total assets in 2024, down from 95.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 8.4% of total assets.
Whitehawk Therapeutics, Inc. Competitors by Total Assets
Key competitors of Whitehawk Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Whitehawk Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.76 | 4.89 | 0.62 |
| Quick Ratio | 16.76 | 4.54 | 0.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $155.19 Million | $61.50 Million | $-11.37 Million |
Whitehawk Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Whitehawk Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 2.01 |
| Asset Growth Rate (YoY) | -46.9% |
| Total Assets | $70.32 Million |
| Market Capitalization | $141.39 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Whitehawk Therapeutics, Inc.'s assets at a significant premium (2.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Whitehawk Therapeutics, Inc.'s assets decreased by 46.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual total assets of Whitehawk Therapeutics, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $70.32 Million | -46.90% |
| 2023-12-31 | $132.42 Million | -28.12% |
| 2022-12-31 | $184.24 Million | +16.67% |
| 2021-12-31 | $157.91 Million | +738.83% |
| 2020-12-31 | $18.82 Million | +13.00% |
| 2019-12-31 | $16.66 Million | -- |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more